MDS个体化风险评估相关因素的研究进展

Research Progress of Individualized Risk Assessment for Myelodysplastic Syndrome

骨髓增生异常综合征(MDS)是多见于老年人的克隆性髓系肿瘤,进展为急性髓系白血病(AML)的风险较高,但MDS患者的死亡通常不是由于疾病进展为AML所致。为此需要制订更为精准合理的MDS个体化预后积分系统,以评估MDS预后风险。现行MDS预后评分系统对评估无白血病生存期和总生存期是有效的,且随着分子数据的加入而进一步完善;在此基础上加入合并症、虚弱和疲劳等患者相关参数将有望提高预后评分系统对总生存期、治疗毒性和医疗费用的预测能力。

Myelodysplastic syndrome(MDS)is a clonal myeloid tumor commonly seen in the elderly.It is at high risk of developing into acute myeloid leukemia(AML),although the death of MDS patients is usually not caused by the progression of the disease to AML.Therefore it is necessary to develop a more accurate and reasonable individual scoring system for MDS prognosis risk assessment.The current MDS prognostic scoring system is effective for evaluating leukemia free survival and overall survival,and will be further improved with the addition of molecular data.On this basis,the addition of complications,weakness and fatigue and other patient-related parameters is expected to improve the predictive ability of the prognostic scoring system for the overall survival,treatment toxicity and medical costs.